Rare lephants
Screener

CRISPR Therapeutics AG

CRSP ·Healthcare, Drug Manufacturers - General
Analysis › Moat Score

Moat Score — CRISPR Therapeutics AG

Total Moat Score 13 / 30
Moat Factor Score Analysis
Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. 5 / 5 Foundational CRISPR/Cas9 IP co-originated by a Nobel laureate founder, combined with being first to an approved gene-editing therapy (CASGEVY), constitutes a formidable intangible asset base.
Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. 1 / 5 As a clinical-stage biotech with minimal revenue and heavy R&D/manufacturing costs, CRISPR Therapeutics has no cost advantage versus peers or incumbents.
Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. 3 / 5 CASGEVY commands a multi-million-dollar one-time price reflecting its curative positioning for severe genetic blood disorders, though payer/reimbursement negotiations constrain outright pricing power.
Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. 0 / 5 No network effects; value is driven by proprietary science and regulatory approvals, not user or platform network dynamics.
Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. 2 / 5 Once a patient receives a one-time gene-editing treatment there is no 'switching,' but treatment center and physician relationships built around CASGEVY create moderate stickiness in the ecosystem.
Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. 2 / 5 The pool of companies capable of running full CRISPR-based clinical and commercial programs is small (Intellia, Beam, Editas), giving some natural scale protection against new entrants.